GeneDx Faces Securities Fraud Lawsuit Following Fabric Genomics Merger

The litigation centers on claims that GeneDx executives artificially inflated share prices by promising seamless technological synergy and AI-driven growth through the acquisition of Fabric Genomics. While the company touted the deal as a catalyst for recurring software revenue and reduced costs, the lawsuit alleges that management concealed significant integration failures and operational disconnects that ultimately compromised the firm’s financial stability.

The facade crumbled on May 4, 2026, when the company revealed a $31.2 million impairment loss on the Fabric unit, effectively wiping out 94% of the cash paid for the asset just one year earlier. Alongside this write-down, GeneDx missed revenue targets for its exome and genome testing lines and slashed its full-year 2026 revenue guidance by up to $75 million. The market reaction was swift, with WGS shares crashing 49.2% in a single session, dropping from $67.93 to $34.51 and erasing billions in shareholder value.

Reed Kathrein, the Hagens Berman partner leading the investigation, contends that investors were misled by management’s persistent positive outlook regarding the integration’s technical efficiencies. The firm is currently evaluating the full scope of these alleged misrepresentations. Investors who purchased shares between April 16, 2025, and May 4, 2026, are encouraged to contact the firm before the August 3 deadline. Additionally, legal counsel is inviting potential whistleblowers with non-public information to assist in the probe, noting the potential for rewards under SEC programs.